ArticlePloS one2025
Circular RNA FTO functions as a hsa-miR-141-3p sponge to regulate the growth and migration abilities of human retinal endothelial cells via up-regulating ZEB1.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative diabetic retinopathy (PDR) is a microvascular complication of diabetes mellitus. Circular RNAs have been implicated in the pathogenesis of PDR. This study aimed to elucidate the specific mechanism by which circFTO contributes to PDR progression. circFTO expression was significantly upregulated in PDR patients and in high glucose (HG)-treated human retinal endothelial cells (HRECs). Knockdown of circFTO suppressed cell proliferation, migration, and tube formation in HG-treated HRECs. Furthermore, hsa-miR-141-3p levels were downregulated, while ZEB1 levels were upregulated in HG-treated HRECs. Dual-luciferase reporter assays demonstrated that hsa-miR-141-3p directly interacts with both circFTO and ZEB1. Additionally, hsa-miR-141-3p silencing reversed the effects of circFTO knockdown, and ZEB1 overexpression counteracted the effects of hsa-miR-141-3p mimic transfection. These findings suggest that circFTO promotes PDR progression via the hsa-miR-141-3p/ZEB1 axis. Collectively, our findings provide preliminary mechanistic insights into the role of circFTO in PDR progression, suggesting its potential as a candidate for further investigation as a diagnostic biomarker or therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.